Viracta Therapeutics Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $5 to $3.
Viracta Therapeutics Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $5 to $3.
Leerink Partners將Viracta Therapeutics的股票評級從跑贏大盤降爲市場表現，並將其目標價從5美元降至3美元后，該股股價下跌。
Viracta Therapeutics Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $5 to $3.
Leerink Partners將Viracta Therapeutics的股票評級從跑贏大盤降爲市場表現，並將其目標價從5美元降至3美元后，該股股價下跌。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。